Gene expression of vasoactive intestinal peptide receptors in human lung cancer

Maria Szilasi, Armin Buglyo, Andrea Treszl, Lili Kiss, Andrew V Schally, Gabor Halmos

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Despite significant improvement in the diagnosis and treatment of various human carcinomas, the 5-year survival rate for lung cancer remains below 20%. Vasoactive intestinal peptide (VIP) is an important neuropeptide in the control of lung physiology, and exerts its functions mainly through two receptor subtypes, VPAC1 and VPAC2. Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. The aim of the present study was to investigate by RT-PCR the mRNA expression of the VPAC1 and VPAC2 receptors in surgical specimens of 43 human lung cancer specimens and 7 normal lung samples. mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%. Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16% displayed only the VPAC2 receptor, while 13 samples (30%) expressed neither subtype. Thirteen cancer tissue specimens (30%), expressed both of these VIP receptor subtypes. Three normal lung tissue specimens also displayed gene expression for VPAC1 and/or VPAC2 receptors. Our results support the additional investigation of the role of VIP and its receptors in human lung cancer and suggest a further development of VIP analogs for therapeutic and imaging purposes in this malignancy.

Original languageEnglish
Pages (from-to)1019-1024
Number of pages6
JournalInternational Journal of Oncology
Volume39
Issue number4
DOIs
StatePublished - Oct 1 2011

Fingerprint

Receptors, Vasoactive Intestinal Polypeptide, Type I
Vasoactive Intestinal Peptide Receptors
Receptors, Vasoactive Intestinal Peptide, Type II
Lung Neoplasms
Gene Expression
Messenger RNA
Vasoactive Intestinal Peptide
Lung
Neoplasms
Neuropeptides
Carcinoma
Polymerase Chain Reaction
Incidence

Keywords

  • Lung cancer
  • Vasoactive intestinal peptide
  • VPAC1 and VPAC2 receptors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gene expression of vasoactive intestinal peptide receptors in human lung cancer. / Szilasi, Maria; Buglyo, Armin; Treszl, Andrea; Kiss, Lili; Schally, Andrew V; Halmos, Gabor.

In: International Journal of Oncology, Vol. 39, No. 4, 01.10.2011, p. 1019-1024.

Research output: Contribution to journalArticle

Szilasi, Maria ; Buglyo, Armin ; Treszl, Andrea ; Kiss, Lili ; Schally, Andrew V ; Halmos, Gabor. / Gene expression of vasoactive intestinal peptide receptors in human lung cancer. In: International Journal of Oncology. 2011 ; Vol. 39, No. 4. pp. 1019-1024.
@article{a30a52b919b54ebc9cb9eb9ae897e2b1,
title = "Gene expression of vasoactive intestinal peptide receptors in human lung cancer",
abstract = "Despite significant improvement in the diagnosis and treatment of various human carcinomas, the 5-year survival rate for lung cancer remains below 20{\%}. Vasoactive intestinal peptide (VIP) is an important neuropeptide in the control of lung physiology, and exerts its functions mainly through two receptor subtypes, VPAC1 and VPAC2. Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. The aim of the present study was to investigate by RT-PCR the mRNA expression of the VPAC1 and VPAC2 receptors in surgical specimens of 43 human lung cancer specimens and 7 normal lung samples. mRNA expression of the VPAC1 receptor was detected in 51{\%} of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46{\%}. Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16{\%} displayed only the VPAC2 receptor, while 13 samples (30{\%}) expressed neither subtype. Thirteen cancer tissue specimens (30{\%}), expressed both of these VIP receptor subtypes. Three normal lung tissue specimens also displayed gene expression for VPAC1 and/or VPAC2 receptors. Our results support the additional investigation of the role of VIP and its receptors in human lung cancer and suggest a further development of VIP analogs for therapeutic and imaging purposes in this malignancy.",
keywords = "Lung cancer, Vasoactive intestinal peptide, VPAC1 and VPAC2 receptors",
author = "Maria Szilasi and Armin Buglyo and Andrea Treszl and Lili Kiss and Schally, {Andrew V} and Gabor Halmos",
year = "2011",
month = "10",
day = "1",
doi = "10.3892/ijo.2011.1122",
language = "English",
volume = "39",
pages = "1019--1024",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Gene expression of vasoactive intestinal peptide receptors in human lung cancer

AU - Szilasi, Maria

AU - Buglyo, Armin

AU - Treszl, Andrea

AU - Kiss, Lili

AU - Schally, Andrew V

AU - Halmos, Gabor

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Despite significant improvement in the diagnosis and treatment of various human carcinomas, the 5-year survival rate for lung cancer remains below 20%. Vasoactive intestinal peptide (VIP) is an important neuropeptide in the control of lung physiology, and exerts its functions mainly through two receptor subtypes, VPAC1 and VPAC2. Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. The aim of the present study was to investigate by RT-PCR the mRNA expression of the VPAC1 and VPAC2 receptors in surgical specimens of 43 human lung cancer specimens and 7 normal lung samples. mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%. Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16% displayed only the VPAC2 receptor, while 13 samples (30%) expressed neither subtype. Thirteen cancer tissue specimens (30%), expressed both of these VIP receptor subtypes. Three normal lung tissue specimens also displayed gene expression for VPAC1 and/or VPAC2 receptors. Our results support the additional investigation of the role of VIP and its receptors in human lung cancer and suggest a further development of VIP analogs for therapeutic and imaging purposes in this malignancy.

AB - Despite significant improvement in the diagnosis and treatment of various human carcinomas, the 5-year survival rate for lung cancer remains below 20%. Vasoactive intestinal peptide (VIP) is an important neuropeptide in the control of lung physiology, and exerts its functions mainly through two receptor subtypes, VPAC1 and VPAC2. Receptors for VPAC1 and VPAC2 are present in human lung cancer cells, but very limited information exists about the mRNA expression of these VIP receptor subtypes in lung cancer specimens. The aim of the present study was to investigate by RT-PCR the mRNA expression of the VPAC1 and VPAC2 receptors in surgical specimens of 43 human lung cancer specimens and 7 normal lung samples. mRNA expression of the VPAC1 receptor was detected in 51% of the tumor specimens, while the incidence of mRNA expression for VPAC2 was 46%. Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16% displayed only the VPAC2 receptor, while 13 samples (30%) expressed neither subtype. Thirteen cancer tissue specimens (30%), expressed both of these VIP receptor subtypes. Three normal lung tissue specimens also displayed gene expression for VPAC1 and/or VPAC2 receptors. Our results support the additional investigation of the role of VIP and its receptors in human lung cancer and suggest a further development of VIP analogs for therapeutic and imaging purposes in this malignancy.

KW - Lung cancer

KW - Vasoactive intestinal peptide

KW - VPAC1 and VPAC2 receptors

UR - http://www.scopus.com/inward/record.url?scp=79960884921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960884921&partnerID=8YFLogxK

U2 - 10.3892/ijo.2011.1122

DO - 10.3892/ijo.2011.1122

M3 - Article

C2 - 21769421

AN - SCOPUS:79960884921

VL - 39

SP - 1019

EP - 1024

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -